G
Genprex, Inc. (GNPX)
NCM – Real vaqt narxi. Valyuta: USD
1.82
-0.06 (-3.19%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.86
+0.04 (2.47%)
Bozordan keyin: Mar 27, 2026, 7:59 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NCM – Real vaqt narxi. Valyuta: USD
1.82
-0.06 (-3.19%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.86
+0.04 (2.47%)
Bozordan keyin: Mar 27, 2026, 7:59 PM EDT
Genprex, Inc., klinik tadqiqot bosqichidagi gen terapiyasi kompaniyasi, saraton va diabet bilan og'rigan bemorlar uchun davolash usullarini ishlab chiqishga qaratilgan. Kompaniyaning texnologiyalari saraton va diabet bilan og'rigan bemorlar uchun yangi davolash usullarini taqdim etish uchun kasalliklarga qarshi kurashuvchi genlarni etkazib berishga mo'ljallangan. Uning onkologiya dasturi lipid asosidagi nanozarralar yordamida genlarni ifodalovchi plazmidalarni lipoplex shaklida o'rab oladigan Oncoprex Delivery System tizimidan foydalanadi. Kompaniyaning asosiy mahsulot nomzodi, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), NSCLC va SCLC davolash uchun uchta klinik sinovda baholanmoqda. Uning uchta o'pka saratoni bo'yicha klinik dasturlari ushbu bemorlar uchun FDA tomonidan Fast Track Designation ni olgan va SCLC dasturi FDA Orphan Drug Designation ni olgan. Kompaniyaning diabet gen terapiyasi Pdx1 va MafA genlarini to'g'ridan-to'g'ri oshqozon osti beziga etkazib berish uchun AAV vektoridan foydalanadigan yangi infuziya jarayonini o'z ichiga oladi. 1-toifali diabet modellarida GPX-002 oshqozon osti bezidagi alfa hujayralarini insulin ishlab chiqaradigan, ammo beta hujayralaridan farq qiladigan va shu bilan organizmning immunitet tizimidan qochib qutula oladigan funktsional beta-hujayralarga aylantiradi; va avtoimmunitet mavjud bo'lmagan 2-toifali diabet uchun GPX-002, charchagan beta hujayralarni yoshartiradi va to'ldiradi deb ishoniladi. U Michigan universiteti Rogel saraton markazi bilan tadqiqot shartnomasiga va ALK Positive bilan o'pka saratonini o'rganish hamkorligiga ega. Genprex, Inc. 2009 yilda tashkil etilgan va Ostin, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jack A. Roth F.A.C.S., M.D. | Chairman of Scientific & Medical Advisory Board |
| Dr. Mark S. Berger M.D. | Chief Medical Officer |
| Dr. Suzanne Thornton-Jones Ph.D. | Senior Vice President of Regulatory Affairs & Quality |
| Mr. David M. Schloss | Senior Vice President of Human Resources |
| Mr. Ryan M. Confer M.S. | President, CEO, CFO & Director |
| Mr. Thomas C. Gallagher Esq. | Senior Vice President of Intellectual Property & Licensing |
| Ms. Celina Laney | Chief of Staff |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-18 | 8-K | gnpx20260316_8k.htm |
| 2026-01-09 | S-8 | gnpx20251229_s8.htm |
| 2026-01-07 | 8-K | gnpx20260105_8k.htm |
| 2026-01-06 | 8-K | gnpx20251201_8k.htm |
| 2025-12-23 | 8-K | gnpx20251216_8k.htm |
| 2025-11-26 | S-1/A | gnpx20251126_s1a.htm |
| 2025-11-21 | 8-K | gnpx20251120_8k.htm |
| 2025-11-19 | 8-K | gnpx20251116c_8k.htm |
| 2025-11-18 | 8-K | gnpx20251116_8k.htm |
| 2025-11-14 | S-8 | gnpx20251111_s8.htm |